转移性男性乳腺癌：一项回顾性队列分析。
Metastatic male breast cancer: a retrospective cohort analysis.
作者信息
Foerster Robert, Schroeder Lars, Foerster Frank, Wulff Volker, Schubotz Birgit, Baaske Dieter, Rudlowski Christian
机构信息
Department of Radiation Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
Department of Gynecology and Obstetrics, University Hospital, Center of Integrated Oncology (CIO) Bonn, Germany.
出版信息
Breast Care (Basel). 2014 Apr;9(4):267-71. doi: 10.1159/000365953.
BACKGROUND
Metastasized male breast cancer (MMBC) is a rare disease. Given its low incidence, data regarding tumor biology, current treatment options, and survival rates are scarce.
PATIENTS AND METHODS
A chart review was performed of MMBC patients consecutively registered in regional cancer registries in Germany between 1995 and 2011. Tumor characteristics, treatment, and survival rates were documented and statistically evaluated.
RESULTS
41 men with MMBC represented 25.6% of a total of 160 patients with MBC. 16 (39%) patients showed primary metastases, and 25 (61%) had recurrent metastases. Median survival from occurrence of metastasis was 32 months. Median overall survival (OS) was 68 months. 68.3% (n = 28) of the cohort received systemic therapy favoring endocrine therapy (n = 25, 61.9%). Prolonged metastatic OS (p = 0.02) was observed in patients having had a systemic treatment. Metastatic patients having received endocrine treatment showed significantly prolonged survival rates. Furthermore, patients receiving palliative chemotherapy had a significant survival benefit compared to those in whom chemotherapy was omitted.
CONCLUSION
Our results suggest that systemic treatment in the form of both palliative chemotherapy and endocrine therapy improves outcome of R. Foerster and L. Schroeder contributed equally to this article and are listed in alphabetical order. MMBC. Therefore, it seems reasonable that treatment of MMBC should be based on the guidelines for female breast cancer.
背景
转移性男性乳腺癌（MMBC）是一种罕见疾病。鉴于其发病率低，关于肿瘤生物学、当前治疗选择和生存率的数据稀缺。
患者与方法
对1995年至2011年间在德国地区癌症登记处连续登记的MMBC患者进行了病历回顾。记录并统计评估了肿瘤特征、治疗情况和生存率。
结果
41例MMBC男性患者占160例MBC患者总数的25.6%。16例（39%）患者出现原发性转移，25例（61%）有复发性转移。转移发生后的中位生存期为32个月。中位总生存期（OS）为68个月。该队列中68.3%（n = 28）的患者接受了全身治疗，其中倾向于内分泌治疗（n = 25，61.9%）。接受全身治疗的患者观察到转移性OS延长（p = 0.02）。接受内分泌治疗的转移性患者生存率显著延长。此外，接受姑息化疗的患者与未接受化疗的患者相比有显著的生存获益。
结论
我们的结果表明，姑息化疗和内分泌治疗形式的全身治疗可改善MMBC的预后。R. Foerster和L. Schroeder对本文贡献相同，按字母顺序列出。因此，MMBC的治疗应基于女性乳腺癌指南似乎是合理的。
Zotero 插件